Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tc 99m Tilmanocept Imaging for Predicting Anti-TNFα Response in RA
NCT05246280Phase 3Terminated
- Sponsor
- Navidea Biopharmaceuticals, Inc.
- Start
- Mar 2022
- Primary completion
- Jul 2024
- Modality
- Radiopharmaceutical, Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of technetium tc 99m tilmanocept in rheumatoid arthritis (RA), sponsored by Navidea Biopharmaceuticals, Inc. Primary endpoints: Specificity of Tilmanocept Uptake Value up to 213 days and Sensitivity of Tilmanocept Uptake Value up to 213 days. Started Mar 2022; status: terminated.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05246280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05246280.